Despite a turbulant year for critical illness rates, sales remain strong. However, the market awaits the launch of new products with baited breath, writes Kirstie Redford Click here to download pdf
As any adviser working in the market will know, over the past 12 months we have seen one of the most eventful periods in the critical illness (CI) market to date. Diagnostic developments and a predicted claims explosion have led underwriters to reassess risk and make some complex decisions about current offerings. Events have snowballed since Swiss Re decided to turn its back on guaranteed rates last year, leading many providers to ditch popular guarantees altogether or hike prices to cover the added risk. More reviewable rates have been launched, but prices for guaranteed plans have ...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
